| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
*
Department of Medicine 1 and
Department of Laboratory Medicine, Istituto Scientifico San Raffaele, Milan, Italy; and
Department of Medicine, University of Bristol, Bristol, United Kingdom
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
300 amino acids and a short region (juxtamembrane
domain) of <100 amino acids, which links the PTP-like domain to the
membrane anchoring portion. The lumenal ectodomains of both proteins
are 600 amino acids, most of which are cleaved to yield mature
proteins of 64 kDa (9). The two proteins share 88% amino acid
sequence homology between their PTP-like domains, <50% homology
between their juxtamembrane domains, and only 10% homology between
their ectodomains. IA-2 and IA-2ß are relatively distant from classic
transmembrane PTPs (10), and autoantibodies in diabetes do not
recognize PTPs other than IA-2 and IA-2ß (11). No phosphatase
activity has been found for the IA-2 protein (12), and only weak
activity has been reported for a human clone of IA-2ß (3). Partial
phosphatase activity can be restored by substituting residues
877 and 911 of IA-2 with those found on the classic transmembrane PTPs
(13). The finding of two structurally related autoantigens presents the possibility of studying aspects of the maturation of the autoimmune response in disease. Autoantibodies found in diabetes bind to epitopes within the intracellular portions of IA-2 and IA-2ß, and there is considerable Ab cross-reactivity between the two proteins (4, 7, 11, 14). It has been shown that IA-2 can partially or completely inhibit the binding of autoantibodies to the 37-kDa tryptic islet polypeptide (4, 5, 6) and to IA-2ß (2, 7, 14), indicating that some of the autoantibody epitopes are shared. Epitopes have been recognized in the intracellular region of IA-2 within both the PTP-like and the juxtamembrane domains (11, 15), while for IA-2ß, the epitopes have been only partially identified (14). To determine which are the critical regions for initial autoantibody binding and which of the PTP-like autoantigens is the primary target of humoral autoimmunity, we have analyzed IA-2 and IA-2ß autoantibody epitopes of sera from patients with type 1 diabetes and examined changes in epitope recognition in sequential islet Ab containing samples from relatives of patients. These studies suggest that IA-2-specific epitopes are the initial targets of the diabetes-associated humoral autoimmunity against the PTP autoantigens and have demonstrated intra- and intermolecular spreading to epitopes shared with the structurally related IA-2ß protein, allowing identification of the potentially critical residues involved in this initial humoral response.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Serum samples were obtained within 2 wk of type 1 diabetes onset from 217 patients who presented at the San Raffaele Hospital between 1988 and 1995. Type 1 diabetes was diagnosed according to World Health Organization criteria. Patients had a median age of 12 yr (range, 1–40 yr). Serum samples were obtained from 141 first-degree relatives of patients with type 1 diabetes. All relatives had islet cell Abs (ICA) at >10 Juvenile Diabetes Foundation (JDF) units in at least two consecutive samples. These relatives were identified from all those tested in the Barts-Oxford family study (11). Initial samples and follow-up samples obtained every 1 to 2 yr were included in the study. A total of 441 samples was tested with a median follow-up time of 7 yr (range, 0.02–11.9 yr). Of these, 17 developed type 1 diabetes after the collection of the initial blood sample (median time to diabetes, 4.8 yr; range, 0.02–11.25 yr). Serum was also obtained from 80 normal children and blood donors in the Milan area. Control subjects had a median age of 12 yr (range, 1 to 40 yr); 37 of these were male.
Cloning of IA-2 and IA-2ß constructs
Constructs used in this study are shown in Figure 1
. The IA-2605–979 construct
was used to identify IA-2 Abs. The IA-2389–779 and
IA-2605–682 constructs were used to identify Abs binding
to the juxtamembrane region of IA-2, and the IA-2687–979
construct was used for Abs binding the PTP-like domain of IA-2. These
were prepared in the pSP64 poly(A) (IA-2605–979)
or pGEM-T (IA-2389–779 and IA-2605–682)
cloning vectors (Promega, Madison, WI) under the control of the
SP6 promoter as described previously (11).
|
The IA-2ßIC-5' primer contains an artificial in-frame start codon followed by an alanine codon to allow efficient expression of the amplified product. A cDNA clone containing a single point mutation, which encodes a stop codon at amino acid 999, was also isolated during the clone screening procedure. The products were cloned into the pGEM-T vector. The IA-2ß662–1033 construct was used to identify IA-2ß Abs. The IA-2ß662–744 construct was used for identification of Abs binding to the juxtamembrane region of IA-2ß, and the IA-2ß741–1033 construct was used for Abs binding the PTP-like domain of IA-2ß. For bacterial expression, the cDNAs were subcloned into the pTrcHis vector (Invitrogen, San Diego, CA).
Based upon the deposited sequence of the rat homologue of IA-2ß (phogrin; GenBank accession no. Z50735), a cDNA encoding the intracellular portion (amino acids 629-1004) of the rat protein was PCR amplified from reverse-transcribed RIN 5AH cells total RNA, with the specific primers phogrin-IC-5', 5'-ATGCGCCACAACTCACACTACAAGCTGAA-3' and phogrin-IC-3', 5'-CTACACAGAAGATGCAGAAATGATAT-3'. The phogrin-IC-5' primer contained an artificial in-frame start codon to allow in vitro transcription/translation. The amplified cDNA was cloned into the pGEM-T vector.
Chimeric IA-2/IA-2ß PTP domains. The following chimeric IA-2/IA-2ß PTP domains were obtained by in-frame joining of selected portions of the IA-2 and IA-2ß: IA-2687–889/IA-2ß943–1033; IA-2ß741–942/IA-2890–979; IA-2687–794/IA-2ß849–942/IA-2ß890–979; and IA-2ß741–848/IA-2795–889/IA-2ß943–1033. The IA-2687–889/IA-2ß943–1033 and IA-2ß741–942/IA-2890–979 chimeras were obtained upon PCR amplification of respective IA-2 and IA-2ß cDNA portions with mutagenized primers introducing an EcoRI restriction site, followed by restriction and ligation. Mutagenesis did not affect amino acid sequence. The chimeras IA-2687–794/IA-2ß849–942/IA-2890–979 and IA-2ß741–848/IA-2795–889/IA-2ß943–1033 were originated from the first two using the Seamless (Stratagene, La Jolla, CA) method with appropriate oligonucleotide primers.
Mutagenized IA-2IC proteins. These were obtained and tested upon insertion of single nucleotide changes into the cytoplasmic portion of the IA-2 cDNA by the QuickChange (Stratagene) method using mutagenesis-specific oligonucleotides. The following amino acid residues were modified: aa 877 Ala > Asp; aa 911 Asp > Ala; aa 877 Ala > Asp + aa 911 Asp > Ala.
In vitro translation and immunoassay
Purified plasmid DNA of the constructs was obtained by Qiaquick spin column preparation (Diagen, Hilden, Germany) and in vitro transcribed and translated utilizing the TnT SP6-coupled rabbit reticulocyte lysate system (Promega) in the presence of [35S]methionine (Amersham), according to the manufacturer’s instructions. Unincorporated [35S]methionine was removed by gel chromatography on a NAP5 column (Pharmacia, Uppsala, Sweden). The correspondence of the molecular size for all translated proteins to that predicted from the amino acid sequence was verified by SDS-PAGE and autoradiography. For PTP-like domain constructs, a second smaller product, probably derived from a downstream start codon was also obtained. For immunoassay, 2 µl of serum was added to 25 µl of TBST (50 mM Tris, 150 mM NaCl, pH 7.2, 1% Tween 20) containing 15,000 to 20,000 cpm of labeled recombinant proteins in wells of a 96-deep well plate (Beckman, Fullerton, CA) and incubated overnight on ice. Immune complexes were recovered by adding 1 mg of protein A-Sepharose (Pharmacia) preswollen and resuspended in 50 µl of TBST, then incubated for 1 h at 4°C with shaking. Protein A-Sepharose beads were washed five times with 800 µl of TBST and centrifuged at 600 x g for 3 min to pellet beads between washes. After washing, Sepharose was transferred in 100 µl of TBST to a 96-well Optiplate (Packard, Groningen, The Netherlands), 150 µl of Microscint 40 (Packard) was added, and plates were shaken for 30 min and counted for 5 min in a TopCount (Packard) scintillation counter for measurement of the recovered cpm. In some experiments, protein A-Sepharose pellets were processed in 30 µl of denaturing loading buffer for SDS-PAGE and autoradiography. Results were expressed as arbitrary units relative to a standard curve prepared by measurement in each assay of a serum with high autoantibody levels serially diluted in normal serum. The upper first centile of 80 control sera was used as the threshold of autoantibody detection for each construct. This was 1.5 U for each of IA-2605–979, IA-2ß662–1033, IA-2687–979, IA-2ß741–1033, and 6 U for Abs against the juxtamembrane region of IA-2. Reactivity against the mutagenized IA-2ic proteins was expressed relative to that observed with a mouse anti-IA-2 mAb (76F) that binds to an epitope contained within the juxtamembrane region of IA-2.
Competition experiments
Identification of IA-2 and IA-2ß PTP-like domain-specific and
cross-reactive Abs was performed with competition by the alternate
bacterially expressed PTP-like domain protein in the standard Ab
radiobinding assay. The pTRC-His bacterial expression vector (Xpress
expression and purification system, Invitrogen) containing
IA-2687–979 and IA-2ß741–1033 were
transformed into the INV
F' Escherichia coli strain. After
culturing to early log phase, protein expression was induced by the
addition of 1 mM isopropyl-ß-D-thiogalactopyranoside.
Bacteria were harvested 4 h after induction and resuspended in 10
mM HEPES, 150 mM NaCl (pH 7.4) containing 10 mM benzamidine, 0.1%
aprotinin, and 2% Triton X-100, followed by incubation for 2 h at
4°C with shaking. Insoluble material was removed by centrifugation at
15,000 x g for 15 min. Competition was conducted by
preincubating the sera with the IA-2 or IA-2ß PTP-like domain
preparations containing 5 µg of recombinant protein, or control
E. coli extract, for 1 h at 4°C before adding,
respectively, radiolabeled IA-2ß or IA-2 PTP-like domain and
conducting an immunoassay as described above. Sera were
considered to contain cross-reactive PTP-like domain Abs if binding to
radiolabeled IA-2687–979 was at least partially inhibited
(>10%) by unlabeled IA-2ß741–1033 and binding to
radiolabeled IA-2ß741–1033 was at least
partially inhibited (>10%) by unlabeled IA-2687–979.
Sera were considered to contain IA-2-specific PTP-like domain Abs if
binding could only be detected against the IA-2687–979
protein and not IA-2ß741–1033 or if binding to
IA-2687–979 remained above 1.5 U after competition with
unlabeled IA-2ß741–1033. Sera were considered to contain
IA-2ß-specific Abs if binding to IA-2ß741–1033
remained above 1.5 U after competition with unlabeled
IA-2687–979.
Statistical analysis
A Kaplan-Meier survival analysis was used to determine the cumulative risk of the development of type 1 diabetes. Follow-up time was calculated from the date of the first sample found to contain IA-2 Abs to the date of diabetes onset or last contact. Diabetes-free survival was compared with the log rank test. The 5-yr risks are given as the cumulative risk with a 95% confidence interval (CI) calculated from the SE. The Statistical Package for Social Sciences (SPSS, Chicago, IL) was used for statistical analyses.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
IA-2 Abs were detected in 129 (59%) of 217 patients and in 22
(16%) of 141 relatives with ICA 
10 Juvenile Diabetes
Foundation (JDF) units; Abs to IA-2ß were found in 90 (41%)
patients and 14 (10%) of the relatives (Table I). None had Abs to IA-2ß in the
absence of IA-2 Abs. Among those with IA-2 Abs, reactivity was evenly
distributed between epitopes found within the juxtamembrane region (84
(65%) of 129 patients and 17 (77%) of 22 relatives) and the PTP-like
domain (112 (87%) patients and 17 (73%) relatives); 67 (52%)
patients and 12 (55%) relatives with IA-2 Abs had reactivity to both
regions. None of the sera binding IA-2ß had Abs to construct
IA-2ß662–744 representing the juxtamembrane IA-2ß
region, and all of the reactivity was confined within the PTP-like
domain of IA-2ß (Fig. 2). Sera from 2
patients showed binding to the human IA-2ß, but not to the rat
phogrin, indicating the presence of species-specific Abs. These two
sera did not immunoprecipitate the 37-kDa islet tryptic polypeptide
from rat insulinoma cells as was found in previous studies (11).
Only a few sera bound to the short IA-2ß662–999,
indicating that the C-terminal amino acids are either important for
maintaining correct Ag conformation or contain contact residues for
autoantibody binding.
|
|
). Sera from 24 patients and 3 of the
relatives had Abs that bound the IA-2 PTP-like domain and not the
IA-2ß PTP-like domain (Table II). As
expected, binding to IA-2687–979 in these sera was, for
the most part, unaffected by competition with
IA-2ß741–1047 (e.g., serum 2 and 3, Fig. 3),
although binding in occasional sera could be inhibited by excess
IA-2ß without showing direct binding to in vitro translated IA-2ß;
this suggested the presence of Abs with markedly reduced affinity to
the IA-2ß PTP-like domain as compared with the IA-2 PTP-like domain
(data not shown). All sera with binding to both IA-2 and IA-2ß
PTP-like domains had Abs that recognized epitopes shared between the
two molecules, since binding could be at least partially inhibited by
either IA-2 or IA-2ß PTP-like domains (e.g., sera 4–6, Fig. 3). In
most, but not all, of these serum samples, binding to the IA-2 PTP-like
domain was not completely inhibited by competition with IA-2ß, and
therefore these sera also contained IA-2-specific PTP-like
domain Abs (e.g., sera 4 and 6, Fig. 3). Competition with increased
amounts of IA-2ß did not further reduce binding, indicating that
incomplete inhibition was not due to insufficient competitor. For a
minority of the serum samples, binding to IA-2ß could not be
completely inhibited by competition with excess IA-2, indicating the
presence of Abs that recognized IA-2ß-specific epitopes (e.g., sera 4
and 5, Fig. 3).
|
|
). Ab epitopes in seroconverters
Of the 22 first-degree relatives with IA-2 or IA-2ß Abs, 4 had
undetectable Ab levels in their initial sample and developed
IA-2/IA-2ß Ab reactivity during follow-up (shown in Table III). In each of the 4 relatives Abs were
reactive with IA-2-specific epitopes, either in the juxtamembrane
region or the PTP-like domain, in the first sample in which Abs were
detected. In 3 of these subjects (A, B, and D in Table III), binding to
IA-2 could not be inhibited with rIA-2ß (data not shown). One had Abs
to IA-2-specific PTP-like domain epitopes only (A), one to IA-2
juxtamembrane epitopes only (D), and one to both IA-2-specific PTP-like
domain and juxtamembrane region epitopes (B). In relatives A and B,
subsequent samples had additional Abs that bound to epitopes shared
between the PTP-like domains of IA-2 and IA-2ß. In relative C, Abs
binding to IA-2-specific PTP-like domain epitopes were detected
concurrently with weak Abs to PTP-like domain epitopes shared between
IA-2 and IA-2ß. Both Ab neucleotides increased in titer in
subsequent samples.
|
To identify which IA-2 residues were involved in the binding of
the IA-2-specific PTP-like domain Abs, IA-2/IA-2ß chimeric constructs
were made. Sera with IA-2-specific PTP-like domain Abs only showed
binding to chimeras
IA-2687–889/IA-2ß943–1033 and
IA-2ß741–848/IA-2795–889/IA-2ß943–1033,
which contained IA-2 residues 795 to 889, but not to chimeras
IA-2ß741–942/IA-2890–979 and
IA-2687–794/IA-2ß849–942/IA-2ß890–979,
which lacked these residues (Fig. 4). The
IA-2ß-specific Abs showed binding to
IA-2ß741–942/IA-2890–979 and none of the
other constructs, indicating that IA-2ß-specific residues within both
regions 741–848 and 849–942 were necessary for Ab binding. Abs
binding epitopes shared between IA-2 and IA-2ß bound all constructs.
A comparison of IA-2 and IA-2ß PTP-like domains is shown in Figure 5. Within IA-2795–889,
IA-2-specific residues 804, 813, 821, 822, 862, 876, 877, 878, 880, and
886 represent nonconserved changes, and residues 815, 818, 829, 830,
834, 860, 867, 882, and 884 represent conserved differences between
IA-2 and IA-2ß.
|
|
).
|
Life table analysis in relatives with ICA showed that those also
having Abs to IA-2 or IA-2ß had a markedly increased progression to
type 1 diabetes with a 5-yr risk of 40% (95% CI, 18–62) compared
with 3.7% (95% CI, 0.2–7.2) in relatives without these Abs
(p < 0.0001). Among those with IA-2/IA-2ß
Abs, progression to diabetes was not associated with any one of the Ab
epitope specificities identified. Progression was, however, increased
in those with multiple epitope reactivity. The 5-yr cumulative risk in
those with >2 reactivities was 79% (95% CI, 44–100) vs 23% (95%
CI, 1–45) in those with 1 or 2 reactivities (p
= 0.01) (Fig. 7). Two relatives with a
single IA-2/IA-2ß epitope reactivity developed diabetes, and in both
of them, Abs were against the IA-2 juxtamembrane region (Table II).
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Previous studies have suggested that autoimmunity to IA-2ß rather than IA-2 may be more associated with the development of type 1 diabetes. This is based upon the suggestion that IA-2ß may be more strongly expressed in ß cells than is IA-2 and that Abs to IA-2ß are less frequently detected in control subjects (2). Our findings do not support this view, since many patients had IA-2 Abs in the absence of IA-2ß Abs, and importantly, several relatives developed the disease having only IA-2-specific epitope reactivity. We did find, however, that relatives with multiple IA-2/IA-2ß epitope reactivity had a more frequent and rapid diabetes development. Thus, spreading of autoimmunity to other epitopes, including those found on IA-2ß, appears to be associated with the development of clinical disease. The more rapid progression in those with multiple IA-2/IA-2ß reactivity may simply reflect their identification at a later stage of preclinical disease. However, studies in offspring of parents with type 1 diabetes suggest that multiple Ag reactivity often occurs very early in life (18). Autoantibodies to multiple autoantigen determinants from different autoantigens has also been found associated with an increased likelihood of progression to disease in several studies (19, 20, 21), and therefore, both a high level and a wide range of humoral islet autoimmunity appear to be important covariates of diabetes risk. Of note is our previous demonstration that the detection of IA-2/IA-2ß Abs, using extracts of rat insulinoma cell lines in relatives with ICA, was associated with a more rapid progression to diabetes than that of relatives with ICA and autoantibodies to glutamic acid decarboxylase and/or insulin only (19). Estimation of the risk associated with individual Ab specificities is problematic because of the variable presence of Abs to other autoantigens. Progression to disease in relatives, however, does occur regardless of which Ab specificities are detected, and we suggest that in relatives, the predictive value of autoantibodies appears to be less dependent upon the overall specificity of the autoantibodies than the broadness of the reactivity.
We have identified potential key residues involved in the initial humoral response to IA-2. IA-2-specific residues in both the juxtamembrane and PTP-like domains appear to be important in early Ab recognition of Ag. The IA-2 juxtamembrane region (amino acids 601–682), in particular, appears to harbor unique entire epitopes not found in IA-2ß, and many patients and relatives have Abs that recognize only this region of the IA-2 protein. Ab binding to IA-2/IA-2ß PTP-like domain chimeras determined that the amino acids that are critical for Ab recognition of the IA-2-specific PTP-like domain epitopes are contained within residues 794–889 of the IA-2 protein. Within this region, there are a total of 19 residues that differ between IA-2 and IA-2ß, 9 of which represent only conserved changes. This finding needs to be confirmed using IA-2 with specific mutations and in studies examining the epitope specificities of IA-2/IA-2ß that appear in the first years of life, but their identification is of potential importance for disease prevention. Identification of residues that stimulate autoimmunity but are not essential for function may enable the genetic engineering of functionally intact ß cells with a lower capacity to induce or restimulate autoimmunity. Knowing these residues may also be helpful in designing vaccines. Immunization with either insulin or glutamic acid decarboxylase autoantigens in animal models of diabetes can induce T cell tolerance and delay diabetes onset (22, 23, 24). Thus far, there are no studies showing that IA-2/IA-2ß or peptides of these Ags can induce T cell or B cell tolerance or prevent diabetes in these models. Moreover, humoral autoimmunity to IA-2 and IA-2ß does not appear to be a feature of these animals (25). It still remains unclear whether immunization with any of the diabetes-associated Ags can induce tolerance in man, especially after autoimmunity has been initiated. Nevertheless, several proposed intervention strategies are based on the principle that Ag-induced modulation of the chronic inflammation leading to diabetes is possible either through tolerance induction or, more likely, specific regulation and/or Th2-like immune activation. Since IA-2 and IA-2ß are expressed within islet ß cells, it is expected that induction of Th2-like immunity against these proteins may also delay disease onset. Maintenance of residues that readily promote Ab responses is likely to be useful in the development of strategies for vaccination with Ag, during which an induction of a protective Th2-like immunity is desired.
Other IA-2 residues appear to be important for structure and function as well as Ab binding (13, 15). Residue 911 has been shown to restore partial classic PTPase activity of IA-2 if changed to an alanine; this activity was further enhanced by the additional change of residue 877 to an aspartic acid. The finding that these changes also affect binding of autoantibodies to the PTP-like domain suggests that they may be important for overall PTP-like domain structure. Residue 877 is interesting because it is an aspartic acid in native IA-2ß, and it would therefore be expected that the cross-reactive PTP-like domain Abs would preferentially bind to IA-2. Evidence for the presence of Abs that recognize both IA-2 and IA-2ß PTP-like domains with different affinities is given by the ability of IA-2ß741–1047 to compete for the binding of IA-2687–979 in the absence of direct binding to IA-2ß741–1047 in some sera. Finally, sera from two patients in our study had Abs that bound to human but not rat IA-2ß. Both of these patients had cross-reactive PTP-like domain Abs but not IA-2ß-specific Abs. Therefore, residues that are not conserved between the rat and human IA-2ß PTP-like domains must be involved in the Ab recognition of some of the epitopes that are shared between IA-2 and IA-2ß. Since only a minority of sera with cross-reactive PTP-like domain Abs did not bind to rat IA-2ß, it is likely that there are several different epitopes that are shared between IA-2 and IA-2ß.
In conclusion, this study shows that autoantibody binding to the PTP-like autoantigens associated with type 1 diabetes is most frequently against IA-2 rather than IA-2ß; that almost all individuals with IA-2/IA-2ß Abs have Abs that bind specifically to IA-2 and not IA-2ß; and that these IA-2-specific Abs are most frequently those that can be identified in the early Ab response to IA-2/IA-2ß. These findings suggest that IA-2 is the primary PTP-like autoantigen in type 1 diabetes. Potentially critical residues for the recognition of the IA-2-specific epitopes have been identified, and their identification may be useful for the design of analogues that can be used for preventing destructive autoimmunity. The finding of an increased disease risk associated with increased diversity of the Ab reactivity to IA-2/IA-2ß epitopes suggests that studying this diversity may assist in disease prediction and, moreover, may be a valuable inclusion as a surrogate marker when evaluating the efficacy of intervention therapies to prevent type 1 diabetes.
|
Acknowledgments |
|---|
|
Footnotes |
|---|
2 Address correspondence and reprint requests to Dr. Ezio Bonifacio, Department of Internal Medicine, Istituto Scientifico San Raffaele, via Olgettina 60, Milan 20132, Italy.
3 Abbreviations used in this paper: PTP, protein tyrosine phosphatase; IA-2, islet cell Ag 512; IA-2ß, phogrin/islet cell Ag-related PTP; ICA, islet cell Abs; ICAAR, islet cell autoantigen-related; aa, amino acid; CI, confidence interval; TBST, Tris, 50 mM/NaCl, 150 mM, pH 7.2/1% Tween 20; 37-kDa, 37-kDa proteolytic fragments.
Received for publication January 21, 1998. Accepted for publication May 5, 1998.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
This article has been cited by other articles:
|
|
 |
|
  A. Makinen, T. Harkonen, J. Ilonen, M. Knip, and the Finnish Pediatric Diabetes Register Characterization of the humoral immune response to islet antigen 2 in children with newly diagnosed type 1 diabetes. Eur. J. Endocrinol., July 1, 2008; 159(1): 19 - 26. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Kuhle, C. Pohl, M. Mehling, G. Edan, M. S. Freedman, H.-P. Hartung, C. H. Polman, D. H. Miller, X. Montalban, F. Barkhof, et al. Lack of Association between Antimyelin Antibodies and Progression to Multiple Sclerosis N. Engl. J. Med., January 25, 2007; 356(4): 371 - 378. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S Genovese, E Bazzigaluppi, D Goncalves, A Ciucci, M G Cavallo, F Purrello, M Anello, C M Rotella, G Bardini, O Vaccaro, et al. Clinical phenotype and {beta}-cell autoimmunity in Italian patients with adult-onset diabetes. Eur. J. Endocrinol., March 1, 2006; 154(3): 441 - 447. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Pihoker, L. K. Gilliam, C. S. Hampe, and A. Lernmark Autoantibodies in Diabetes Diabetes, December 1, 2005; 54(suppl_2): S52 - S61. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Lampasona, D. Franciotta, R. Furlan, S. Zanaboni, R. Fazio, E. Bonifacio, G. Comi, and G. Martino Similar low frequency of anti-MOG IgG and IgM in MS patients and healthy subjects Neurology, June 8, 2004; 62(11): 2092 - 2094. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Dromey, S. M. Weenink, G. H. Peters, J. Endl, P. J. Tighe, I. Todd, and M. R. Christie Mapping of Epitopes for Autoantibodies to the Type 1 Diabetes Autoantigen IA-2 by Peptide Phage Display and Molecular Modeling: Overlap of Antibody and T Cell Determinants J. Immunol., April 1, 2004; 172(7): 4084 - 4090. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Achenbach, K. Warncke, J. Reiter, H. E. Naserke, A. J.K. Williams, P. J. Bingley, E. Bonifacio, and A.-G. Ziegler Stratification of Type 1 Diabetes Risk on the Basis of Islet Autoantibody Characteristics Diabetes, February 1, 2004; 53(2): 384 - 392. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Skoldberg, G. M. Portela-Gomes, L. Grimelius, G. Nilsson, J. Perheentupa, C. Betterle, E. S. Husebye, J. Gustafsson, A. Ronnblom, F. Rorsman, et al. Histidine Decarboxylase, a Pyridoxal Phosphate-Dependent Enzyme, Is an Autoantigen of Gastric Enterochromaffin-Like Cells J. Clin. Endocrinol. Metab., April 1, 2003; 88(4): 1445 - 1452. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Bearzatto, H. Naserke, S. Piquer, K. Koczwara, V. Lampasona, A. Williams, M. R. Christie, P. J. Bingley, A.-G. Ziegler, and E. Bonifacio Two Distinctly HLA-Associated Contiguous Linear Epitopes Uniquely Expressed Within the Islet Antigen 2 Molecule Are Major Autoantibody Epitopes of the Diabetes-Specific Tyrosine Phosphatase-Like Protein Autoantigens J. Immunol., April 15, 2002; 168(8): 4202 - 4208. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Roberts, G. A. Roberts, K. Löbner, M. Bearzatto, A. Clark, E. Bonifacio, and M. R. Christie Expression of the Protein Tyrosine Phosphatase-like Protein IA-2 During Pancreatic Islet Development J. Histochem. Cytochem., June 1, 2001; 49(6): 767 - 776. [Abstract] [Full Text]
|
|
|
|
|
|
J. Diez, Y. Park, M. Zeller, D. Brown, D. Garza, C. Ricordi, J. Hutton, G. S. Eisenbarth, and A. Pugliese Differential Splicing of the IA-2 mRNA in Pancreas and Lymphoid Organs as a Permissive Genetic Mechanism for Autoimmunity Against the IA-2 Type 1 Diabetes Autoantigen Diabetes, April 1, 2001; 50(4): 895 - 900. [Abstract] [Full Text]
|
|
|
|
|
|
V. Kolm-Litty, S. Berlo, E. Bonifacio, M. Bearzatto, A. M. Engel, M. Christie, A.-G. Ziegler, T. Wild, and J. Endl Human Monoclonal Antibodies Isolated from Type I Diabetes Patients Define Multiple Epitopes in the Protein Tyrosine Phosphatase-Like IA-2 Antigen J. Immunol., October 15, 2000; 165(8): 4676 - 4684. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. E. Naserke, A.-G. Ziegler, V. Lampasona, and E. Bonifacio Early Development and Spreading of Autoantibodies to Epitopes of IA-2 and Their Association with Progression to Type 1 Diabetes J. Immunol., December 15, 1998; 161(12): 6963 - 6969. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
